CRISPR Therapeutics AG (CRSP) Enterprise Value (2016 - 2026)

CRISPR Therapeutics AG has disclosed Enterprise Value across 11 years of filings, most recently posting $2.9 billion for Q2 2026.

• In Q2 2026, Enterprise Value rose 12.81% year-over-year to $2.9 billion; the TTM figure through Jun 2026 stood at $2.9 billion (up 12.81% YoY), while the FY2025 annual figure was $3.1 billion, up 107.55% from the prior year.
• Enterprise Value came in at $2.9 billion for Q2 2026 at CRISPR Therapeutics AG, up from $2.1 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $4.2 billion in Q3 2025 to a low of $1.1 billion in Q1 2025.
• Average Enterprise Value over 5 years is $2.5 billion, with a median of $2.6 billion recorded in 2022.
• Year-over-year, Enterprise Value slumped 72.63% in 2022 and soared 141.03% in 2023.
• Over 5 years, Enterprise Value stood at $1.4 billion in 2022, then soared by 141.03% to $3.3 billion in 2023, then slumped by 55.66% to $1.5 billion in 2024, then jumped by 107.55% to $3.1 billion in 2025, then declined by 4.76% to $2.9 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $2.9 billion in Q2 2026, $2.1 billion in Q1 2026, and $3.1 billion in Q4 2025.